Eli Lilly has announced the FDA approval of Zepbound, the first and only medication specifically designed to treat both moderate-to-severe obstructive sleep apnea (OSA) and obesity in adults. This news could be a game-changer for some professional football players who struggle with these conditions.

A company news release states that: "NFL players are more likely to live with OSA. In the US, moderate-to-severe OSA affects approximately 24 million adults. Most cases – about 58% – are adults who are overweight or living with obesity."

Sleep apnea, characterized by pauses in breathing during sleep, can significantly impact energy levels, focus, and overall health. Combined with obesity, it can be a major obstacle for athletes.

Studies show that Zepbound can significantly improve sleep apnea symptoms and aid in weight loss. In clinical trials, nearly half of participants saw their sleep apnea symptoms disappear entirely. Additionally, adults taking Zepbound lost an average of 18-20% of their body weight.

These improvements can translate to significant benefits on the field. Better sleep leads to increased energy and focus, while weight loss can enhance athletic performance.

However, Zepbound is not without risks. It comes with a list of potential side effects, and some individuals may not be eligible for the medication. It's important to consult with a doctor to determine if Zepbound is the right option.

This new drug offers a promising solution for athletes battling sleep apnea and obesity. With its potential to improve sleep quality, boost energy levels, and promote weight loss, Zepbound could be a valuable tool for NFL players seeking to optimize their performance and overall health.